A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
Inclusion Criteria:
Exclusion Criteria:
Colorado Springs, Colorado 80909, United States
Chevy Chase, Maryland 20815, United States
C.a.b.a., Buenos Aires C1425AGC, Argentina
CABA, Buenos Aires C1419AHN, Argentina
Córdoba, Córdoba Province X5000AAW, Argentina
Rosario, Santa Fe Province S200CFK, Argentina
San Miguel de Tucumán, Tucumán Province 4000, Argentina
Joinville, Santa Catarina 89201-260, Brazil
Bogotá, Cundinamarca 111311, Colombia
Pereira, Risaralda Department 660002, Colombia
Mexico City, Mexico City 11650, Mexico
St-Petersburg, Leningradskaya Oblast' 199106, Russia
Novosibirsk, Novosibirsk Oblast 630117, Russia
Nizhny Novgorod, Volga 603126, Russia
London, E1 2AJ, United Kingdom